Treatment of early-stage Hodgkin lymphoma
Hodgkin lymphoma (HL) has become one of the best curable malignancies today. This is particularly true for patients with early-stage disease. Today, most patients in this risk group are treated with a combination of chemotherapy followed by small-field radiotherapy. More recent clinical trials such as the German Hodgkin Study Group (GHSG) HD10 study demonstrated, that even two cycles of ABVD followed by 20 Gy involved-field radiation therapy (IF-RT) are sufficient and result in more than 90% of patients being cured. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Andreas Engert, John Raemaekers Source Type: research
Clinical presentation and staging of Hodgkin lymphoma
In the present chapter the authors present a brief overview of the diagnostic methods proposed over time for Hodgkin lymphoma (HL) spread detection, moving from surgical procedures, through standard radiological and functional imaging techniques to the present state of the art for HL staging. The main body of the review will be dedicated to the recently published guidelines for lymphoma staging (including HL) agreed by the experts during the 12th International Congress for Malignant Lymphoma in Lugano. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Andrea Gallamini, Martin Hutchings, Safaa Ramadan Source Type: research
Treatment of advanced-stage Hodgkin lymphoma
There is now good evidence that the escalated BEACOPP regimen (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) is more effective in controlling advanced-stage Hodgkin lymphoma (HL) than the widely used ABVD regimen (adriamycin, bleomycin, vinblastine, dacarbazine), but the extra efficacy comes at the expense of both short- and long-term toxicity, and there is debate as to whether overall survival is affected. Baseline prognostic factors have proven of limited utility for determining which patients require more intensive therapy and recent studies have sought to use interim fluoro-...
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Theodoros P. Vassilakopoulos, Peter W.M. Johnson Source Type: research
Hodgkin lymphoma: Late effects of treatment and guidelines for surveillance
Long-term survivors of Hodgkin lymphoma (HL) are at risk for a range of late effects, with second malignant neoplasm and cardiovascular diseases being the leading causes of death in these patients. The excess risks remain significantly elevated decades after treatment, and are clearly associated with extent of treatment exposures. Other late effects have also been identified, such as pulmonary dysfunction, endocrinopathies, muscle atrophy, and persistent fatigue. Systemic documentation of late effects and recognition of treatment- and patient-related risk factors are important, as they inform optimal surveillance and risk-...
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Andrea K. Ng, Flora E. van Leeuwen Source Type: research
Treatment of relapsed and refractory Hodgkin Lymphoma
Despite the high first-line cure rates in patients with Hodgkin Lymphoma (HL) still 10% –20% of patients suffer from relapsed or refractory disease. High-dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) is standard of care for suitable patients with relapsed or refractory HL and allows for cure in approximately 50%. Due to the poor prognosis of high-risk pa tients even with HDCT and ASCT, consolidation strategies have been evaluated to improve the cure rates. For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Bastian von Tresckow, Craig H. Moskowitz Source Type: research
Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results
Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have evidence for refractory disease, is poor and new treatments are needed for patients with progressive disease. HL has a unique tumor microenvironment consisting of a predominance of inflammatory cells and a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Anas Younes, Stephen M. Ansell Source Type: research
Hodgkin lymphoma: Introduction
We would like to welcome you to this issue on Hodgkin lymphoma in the SEMINARS IN HEMATOLOGY. Hodgkin lymphoma was described by Thomas Hodgkin more than 175 years ago and has since become one of the best curable malignancies today. This progress is largely due to advances in radiotherapy and the development of effective multi-agent chemotherapy. Today, more than 80% of all patients affected can be cured with modern risk-adapted treatment. However, there still are substantial differences in current approaches, including the role of radiotherapy in early stage patients and the selection of the best chemotherapy for advanced ...
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Andreas Engert, Theodoros P. Vassilakopoulos Source Type: research
Prognostic factors in hodgkin lymphoma
During the last decades, the prognosis of Hodgkin lymphoma (HL) has been improved significantly with the introduction of effective chemotherapy and the implementation of risk-adapted treatment approaches. Identification of reliable risk factors is crucial to guide treatment over the course of disease. Both clinical and biological factors have been implicated in the prognosis of HL and are often used in prognostic scores to discriminate risk groups. To prevent under- or overtreatment, patients are usually assigned to one of the three widely established risk groups for first-line treatment, based solely on clinical risk fact...
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Paul J. Bröckelmann, Maria K. Angelopoulou, Theodoros P. Vassilakopoulos Source Type: research
Treatment of early favorable and early unfavorable hodgkin lymphoma – combined modality therapy?
Hodgkin lymphoma has become one of the most curable malignancies today. This is particularly true for patients with early stage disease. Today, most patients in this risk group are treated with a combination of chemotherapy followed by small field radiotherapy. More recent clinical trials such as the GHSG HD10 study demonstrated, that even two cycles of ABVD followed by 20Gy IF-RT are sufficient and result in more than 90% of patients being cured. The current treatment for early unfavorable patients is either four cycles of ABVD plus 30Gy IF-RT or two cycles of BEACOPPescalated followed by two cycles of ABVD plus IF-RT. (S...
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Andreas Engert, John Raemaekers Source Type: research
Clinical presentation and staging of Hodgkin Lymphoma
In the present chapter the authors present a brief overview of the diagnostic methods proposed over time for Hodgkin Lymphoma (HL) spread detection, moving from surgical procedures, through standard radiological and functional imaging techniques to the present state of the art for HL staging. The main body of the review will be dedicated to the recently published guidelines for lymphoma staging (including Hodgkin Lymphoma) agreed by the experts during the 12° International Congress for Malignant Lymphoma in Lugano. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Andrea Gallamini, Martin Hutchings, Safaa Ramadan Source Type: research
Treatment of advanced stage hodgkin lymphoma: Who really needs beacopp?
There is now good evidence that the escalated BEACOPP regimen is more effective in controlling advanced stage Hodgkin lymphoma than the widely used ABVD regimen, but the extra efficacy comes at the expense of both short-and long-term toxicity, and there is debate as to whether overall survival is affected. Baseline prognostic factors have proven of limited utility for determining which patients require more intensive therapy and recent studies have sought to use interim FDG-PET evaluation as a means to guide the modulation of treatment, both upwards and downwards in intensity. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Theodoros P. Vassilakopoulos, Peter W.M. Johnson Source Type: research
Hodgkin Lymphoma: Late Effects of Treatment and Guidelines for Surveillance
Long-term survivors of Hodgkin lymphoma are at risk for a range of late effects, with second malignant neoplasm and cardiovascular diseases being the leading causes of death in these patients. The excess risks remain significantly elevated decades after treatment, and are clearly associated with extent of treatment exposures. Other late effects have also been identified, such as pulmonary dysfunction, endocrinopathies, muscle atrophy and persistent fatigue. Systemic documentation of late effects and recognition of treatment- and patient-related risk factors are important, as they inform optimal surveillance and risk-reduct...
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Andrea K. Ng, Flora E. van Leeuwen Source Type: research
Treatment of relapsed and refractory Hodgkin Lymphoma
Despite the high first line cure rates in patients with Hodgkin Lymphoma (HL) still 10-20% of patients suffer from relapsed or refractory disease. High dose chemotherapy (HDCT) followed by autologous stem cell transplant (ASCT) is standard of care for suitable patients with relapsed or refractory HL and allows for cure in approximately 50%. Due to the poor prognosis of high risk patients even with HDCT and ASCT, consolidation strategies have been evaluated to improve the cure rates. For patients with recurrence after HDCT and ASCT, treatment is palliative in most cases. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Bastian von Tresckow, Craig Moskowitz Source Type: research
Novel agents in the treatment of hodgkin lymphoma: biological basis and clinical results
Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. The prognosis for patients who relapse, or have evidence for refractory disease, however is poor and new treatments are needed for patients with progressive disease. HL has a unique tumor microenvironment consisting of a predominance of inflammatory cells and a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 11, 2016 Category: Hematology Authors: Anas Younes, Stephen M. Ansell Source Type: research
Management of Chronic Immune Thrombocytopenia in Children and Adolescents: Lessons from an Austrian National Cross-Sectional Study of 81 Patients
Chronic immune thrombocytopenia (cITP) is often associated with an underlying predisposition towards autoimmunity, recognition of which is relevant to guide treatment. International recommendations on diagnostic steps and therapeutic measures of cITP in childhood exist. However, due to the low prevalence (1-2/100.000) and a variation of availability of immunological and hematological tests and treatments across pediatric units, we postulated that these guidelines are not uniformly adhered to and that immune dysregulation syndromes remained undiscovered. (Source: Seminars in Hematology)
Source: Seminars in Hematology - April 11, 2016 Category: Hematology Authors: J. Sipurzynski, B. Fahrner, R. Kerbl, R. Crazzolara, N. Jones, G. Ebetsberger, B. Jauk, V. Strenger, B. Wohlmuther, W. Schwinger, H. Lackner, C. Urban, W. Holter, M. Minkov, L. Kager, M. Benesch, M.G. Seidel Source Type: research
